New tool aims to boost IUD use for cancer prevention

NCT ID NCT07382583

First seen Feb 03, 2026 · Last updated Jun 20, 2026 · Updated 22 times

Summary

This study is creating a shared decision-making tool to help women and their doctors talk about using a levonorgestrel IUD to prevent endometrial cancer. Researchers will survey 270 women, both with and without the condition, to understand their preferences. The goal is to make it easier for women at risk to consider this prevention option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • The Harris Health System (LBJ)

    RECRUITING

    Houston, Texas, 77026, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

levonorgestrel-releasing intrauterine system (LNG-IUS)

What this could lead to

If successful, this tool could help more women at risk choose an IUD that may lower their chance of developing endometrial cancer.

What could go wrong

This is an early-stage study developing a decision aid, not testing the IUD itself. It may not change actual cancer rates or be widely adopted.

Conditions

The condition(s) this trial relates to.

endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.